Trial · NCT03583697
Results by group765
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 765
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Adverse Events (AEs) by Severity Grade and Study Drug Treatment-emergent Adverse Events (TEAEs) | Sentinel | Participants with any AE | 11 | Participants | |
| Number of Participants With Adverse Events (AEs) by Severity Grade and Study Drug Treatment-emergent Adverse Events (TEAEs) | Randomized Vosoritide | Participants with any AE | 32 | Participants | |
| Number of Participants With Adverse Events (AEs) by Severity Grade and Study Drug Treatment-emergent Adverse Events (TEAEs) | Randomized Placebo | Participants with any AE | 32 | Participants | |
| Number of Participants With Adverse Events (AEs) by Severity Grade and Study Drug Treatment-emergent Adverse Events (TEAEs) | Sentinel | Participants with any SAE | 0 | Participants | |
| Number of Participants With Adverse Events (AEs) by Severity Grade and Study Drug Treatment-emergent Adverse Events (TEAEs) | Randomized Vosoritide | Participants with any SAE | 3 | Participants | |
| Number of Participants With Adverse Events (AEs) by Severity Grade and Study Drug Treatment-emergent Adverse Events (TEAEs) | Randomized Placebo | Participants with any SAE | 6 | Participants | |
| Number of Participants With Adverse Events (AEs) by Severity Grade and Study Drug Treatment-emergent Adverse Events (TEAEs) | Sentinel | Participants with any treatment-related AE | 8 | Participants | |
| Number of Participants With Adverse Events (AEs) by Severity Grade and Study Drug Treatment-emergent Adverse Events (TEAEs) | Randomized Vosoritide | Participants with any treatment-related AE | 29 | Participants | |
| Number of Participants With Adverse Events (AEs) by Severity Grade and Study Drug Treatment-emergent Adverse Events (TEAEs) | Randomized Placebo | Participants with any treatment-related AE | 17 | Participants | |
| Number of Participants With Adverse Events (AEs) by Severity Grade and Study Drug Treatment-emergent Adverse Events (TEAEs) | Sentinel | Participants with any treatment-related SAEs | 0 | Participants | |
| Number of Participants With Adverse Events (AEs) by Severity Grade and Study Drug Treatment-emergent Adverse Events (TEAEs) | Randomized Vosoritide | Participants with any treatment-related SAEs | 0 | Participants | |
| Number of Participants With Adverse Events (AEs) by Severity Grade and Study Drug Treatment-emergent Adverse Events (TEAEs) | Randomized Placebo | Participants with any treatment-related SAEs | 0 | Participants | |
| Number of Participants With Adverse Events (AEs) by Severity Grade and Study Drug Treatment-emergent Adverse Events (TEAEs) | Sentinel | Participants with any AE of CTCAE grade >=3 | 0 | Participants | |
| Number of Participants With Adverse Events (AEs) by Severity Grade and Study Drug Treatment-emergent Adverse Events (TEAEs) | Randomized Vosoritide | Participants with any AE of CTCAE grade >=3 | 2 | Participants | |
| Number of Participants With Adverse Events (AEs) by Severity Grade and Study Drug Treatment-emergent Adverse Events (TEAEs) | Randomized Placebo | Participants with any AE of CTCAE grade >=3 | 3 | Participants | |
| Number of Participants With Adverse Events (AEs) by Severity Grade and Study Drug Treatment-emergent Adverse Events (TEAEs) | Sentinel | Participants who died | 0 | Participants | |
| Number of Participants With Adverse Events (AEs) by Severity Grade and Study Drug Treatment-emergent Adverse Events (TEAEs) | Randomized Vosoritide | Participants who died | 1 | Participants | |
| Number of Participants With Adverse Events (AEs) by Severity Grade and Study Drug Treatment-emergent Adverse Events (TEAEs) | Randomized Placebo | Participants who died | 0 | Participants | |
| Change From Baseline in Height Z-score at Week 52. | Randomized Vosoritide | -0.06 | 95% Confidence Interval -0.26 to 0.15 | Z-score | |
| Change From Baseline in Height Z-score at Week 52. | Randomized Placebo | -0.31 | 95% Confidence Interval -0.48 to -0.13 | Z-score |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03583697/results